Pricing Log in Create free account
Friday 6 November 2026 Export NBIX’s income statement to Excel — free account

Neurocrine Biosciences, Inc.

NBIX Healthcare Drug Manufacturers Specialty & Generic

Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.

Revenue
+41.2%
EPS
−3.67%
Free cash flow
+79.0%

Quarter to September 2026, against a year earlier

160.47 5.58 −3.36%
Market cap
$16.2B
P/E
23.0×
Fwd P/E
20.6×
Dividend yield
—
F-score
7/9
Altman Z
7.80
Beneish M
−2.64
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Neurocrine Biosciences, Inc. 10-K filed Feb 11, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 4:03 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 10, 2025: 26 added · 26 removed · 36 modified; 2 moved without change

  1. Modified · Overview

    Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering , developing, and developingcommercializing life-changing treatments for patients with under-addressed neuropsychiatricneurological, neurologicalpsychiatric, endocrine, and neuroendocrineimmunological disorders.